V Cossiga

Plain English
This study looked at the relationship between epicardial fat tissue (EFT) and obesity by evaluating 56 adults with visceral obesity. It found that people with metabolically unhealthy obesity (MUO) had a significantly thicker layer of epicardial fat—averaging 9.5 mm in men and 7.5 mm in women—compared to those with metabolically healthy obesity (MHO). Specifically, 82.1% of MUO patients showed high EFT values, and even 42.9% of MHO patients had EFT levels above what is considered healthy, indicating that the current definitions of MHO might not accurately reflect cardiovascular risks. Who this helps: This research helps doctors better assess the cardiovascular risks of patients with different types of obesity.

Plain English
This study looked at a new non-invasive test called HVPG-3P to see how well it can predict serious liver problems in patients with advanced liver disease. Researchers found that higher HVPG-3P scores were strongly linked to signs of severe portal hypertension and potential liver-related events. Specifically, HVPG-3P had a 73% chance of accurately predicting complications related to liver issues and performed similarly to other tests like ANTICIPATE and FIB-4. Who this helps: This benefits patients with advanced chronic liver disease by allowing for earlier intervention and better management of their condition.

Plain English
This study looked at how men and women experience acute-on-chronic liver failure (ACLF) differently, particularly in the ICU and during liver transplantation. Researchers found that men are more likely to be admitted with ACLF and have higher death rates compared to women. They also noted that current scoring systems to predict outcomes don't take sex differences into account, which could lead to poorer results for men. Understanding these differences is crucial because it can help create better treatment strategies for both men and women. Who this helps: This helps patients with liver disease, particularly those with ACLF.

Plain English
This research paper looks at how men and women experience hepatic encephalopathy (HE), a brain problem caused by liver failure. It found that men and women may face different rates and types of risks related to HE, but not much is known about how these differences affect treatment or outcomes. Understanding these differences is important for improving how HE is managed and treated for different patients. Who this helps: This helps patients with liver disease and healthcare providers looking to tailor treatments based on gender differences.

Plain English
This study looked at how well noninvasive tests can identify significant portal hypertension and high-risk varices in patients with primary biliary cholangitis and advanced liver disease. Researchers found that the RESIST criteria had a low rate of missed high-risk varices at 2.5%, compared to 9.8% for the Baveno VI criteria and 8.9% for the Expanded Baveno VI criteria. This matters because finding and accurately assessing these risks can help manage patient care more effectively, especially since the severity of liver damage influences test performance. Who this helps: Patients with primary biliary cholangitis and liver disease, as well as their doctors.

Plain English
This study looked at how men and women in Italy experience differences in access to liver transplants from 2017 to 2021. Researchers found that men were more likely to receive a liver transplant than women, even though survival rates after the transplant were similar; for example, men had a 1.13 to 1.20 times higher chance of undergoing a transplant compared to women for liver cirrhosis and liver cancer. It's important because it highlights that women face barriers in getting liver transplants in Italy, calling for better health policies to ensure fair treatment for everyone. Who this helps: This helps patients, particularly women needing liver transplants.

Plain English
This study looked at the impact of the hepatitis D virus (HDV) on both native Italians and immigrants in Italy, examining 515 patients who were positive for hepatitis B. They found that 83.9% of these patients had detectable levels of the virus, with native Italians generally being older and more likely to suffer from severe liver conditions like cirrhosis (70.3% vs. 50.5% in migrants) and liver cancer (14.8% vs. 0.5% in migrants). The findings are important because they show that while severe liver disease is frequent in both groups, many patients actually have milder cases, which suggests that the treatment and care for chronic HDV infections may need to be tailored differently for these populations. Who this helps: This information benefits patients and doctors by providing insights for better management of hepatitis D infections.

Plain English
This research paper focused on the relationship between gut bacteria and how they can affect the treatment of liver cancer (hepatocellular carcinoma or HCC) using immune checkpoint inhibitors (ICIs). It found that certain gut microbes could improve the effectiveness of these cancer treatments by boosting the immune response and improving how the body fights tumors. This is important because if we can harness these gut bacteria, we may have a new way to enhance cancer therapies, although further studies are needed to confirm this potential. Who this helps: This helps patients with liver cancer who are undergoing immunotherapy treatments.

Plain English
This research paper looks at how sex influences the occurrence of liver tumors and the outcomes of treatments for these conditions. The review found that men and women may experience liver diseases differently, with studies indicating that factors like sex hormones and lifestyle choices (such as obesity, alcohol use, and smoking) play significant roles. For example, certain treatments may work better for one sex than the other, leading to different survival rates and disease progression. Who this helps: This helps patients and doctors by providing insights into more personalized treatment approaches based on sex.

Plain English
This study looked at how implementing routine testing for HDV (Hepatitis D virus) among people already positive for Hepatitis B (HBsAg) affected diagnosis rates. Before this new testing approach, only 16.4% of these patients were tested for HDV, but after the change, it was 100%. While the percentage of patients found to have HDV decreased slightly from 16.6% to 10.7%, the total number of diagnosed cases rose significantly from 14 to 52. Who this helps: This benefits patients with Hepatitis B by allowing for earlier identification of those who also have Hepatitis D.

Plain English
This study looked at how hepatitis viruses contribute to liver cancer, specifically hepatocellular carcinoma (HCC). It found that hepatitis B virus (HBV) accounts for about 40% of liver cancer cases globally, while hepatitis C virus (HCV) is responsible for 28-30%, with differences based on geographic location. Understanding this connection is important as it highlights the need for targeted prevention and treatment strategies for liver cancer, especially for those with hepatitis infections. Who this helps: This helps patients with hepatitis B and C, as well as healthcare providers in managing their care.

Plain English
This study examined patients with chronic Hepatitis D virus (HDV) infection in Italy, focusing on their health profiles and whether they could qualify for certain treatments. Out of 5,492 patients tested, 422 (10.2%) were found to be positive for HDV, with many of these patients being younger and having existing liver conditions like cirrhosis or cancer. The findings highlight that a significant number of patients have other health issues that could limit their treatment options, particularly affecting 53% of them. Who this helps: This helps patients with chronic Hepatitis D and their doctors by providing insights into treatment eligibility and the prevalence of other health problems.

Plain English
This study looked at patients with advanced liver disease caused by hepatitis C after they had successful treatment. Out of 575 patients, 98 (17%) experienced serious liver-related issues within five years, most commonly liver cancer. The research found that those with stiffer livers before treatment (over 20 kPa) were more likely to experience these complications, emphasizing the importance of regularly measuring liver stiffness to better predict risks for patients. Who this helps: This information is useful for doctors managing hepatitis C patients to tailor monitoring and treatment plans.

Plain English
This study looked at how sex differences affect various vascular liver diseases, including conditions like vein thrombosis and hereditary hemorrhagic telangiectasia. The review highlighted that these diseases often impact young people, particularly women of childbearing age, and discussed specific considerations for managing pregnancy in these patients. Understanding these differences is important for improving care and treatment options for affected individuals. Who this helps: Patients with vascular liver diseases and their healthcare providers.

Plain English
This study looked at the eating habits and physical activity levels of patients with Primary Biliary Cholangitis (PBC) compared to people without the condition. Researchers found that PBC patients followed a less healthy diet and had lower intake of healthy fats than the healthy controls. For instance, they scored significantly lower on adherence to the Mediterranean diet. This is important because unhealthy lifestyles may increase the risk of worsening liver disease in these patients. Who this helps: This benefits patients with PBC by highlighting the need for lifestyle changes to better manage their health.

Plain English
This study focused on how well a booster shot for COVID-19 works in patients with chronic liver disease (CLD), including those with cirrhosis. Out of 340 patients, 60 (about 17.6%) did not have antibodies after the initial vaccination, but most—88.3%—developed antibodies after receiving the booster. Notably, having certain types of vascular issues and using the mRNA-1273 vaccine improved the chances of a good immune response. Who this helps: This research benefits patients with chronic liver disease and their healthcare providers by showing that booster shots are effective for them.

Plain English
This study looked at a 45-year-old woman with metastatic breast cancer who also tested positive for hepatitis B. Despite the potential risks, she was treated with Ribociclib, and her liver function remained stable throughout the treatment, which is important because hepatitis B can complicate cancer therapy. After 13 months, her cancer showed a partial response to the treatment and then stabilized, demonstrating that Ribociclib can be safely used in patients with hepatitis B. Who this helps: This helps breast cancer patients who also have hepatitis B.

Plain English
This study looked at cholangiocarcinoma (CCA), a difficult-to-treat liver cancer with a very low survival rate of less than 20% over five years. Researchers found that bile acids, which are important in bodily functions, play a role in how CCA develops and progresses. Understanding how bile acids influence this cancer could lead to new treatment options. Who this helps: Patients diagnosed with cholangiocarcinoma.

Plain English
This study looked at how COVID-19 affects people with fatty liver disorders, particularly since both issues have been growing in prevalence. It found that individuals with non-alcoholic fatty liver disease are more likely to experience severe symptoms from COVID-19. Understanding this connection is important because it highlights the need for better healthcare approaches for these patients, especially during health crises. Who this helps: This benefits patients with fatty liver disorders and their healthcare providers.

Plain English
This study looked at how two specific markers (Cytokeratin-18 M30 and M65) in the blood relate to liver damage in people with visceral obesity. Among 48 participants, nearly half had metabolic syndrome, about 94% had fatty liver, and 60% had high liver stiffness. The study found that higher levels of these markers were linked to greater waist size and poorer liver function, making them useful for spotting early signs of liver damage in obese patients. Who this helps: This benefits patients with visceral obesity and their doctors by providing tools to detect liver issues early.

Plain English
This study focused on the rates of acute Delta hepatitis (HDV) in Italy over 30 years, particularly after the hepatitis B vaccination became mandatory in 1991. It found that the incidence of acute HDV cases decreased dramatically from 3.2 cases per million people in 1987 to just 0.04 in 2019, while cases of hepatitis B also dropped significantly. The findings highlight the success of the vaccination campaign in controlling the spread of HDV and indicate that risky sexual behavior is now the main factor for new infections. Who this helps: This helps patients at risk of hepatitis, healthcare providers, and public health officials.

Plain English
This study looked at how effective and safe a treatment called radiofrequency ablation (RFA) is for patients with liver cancer (hepatocellular carcinoma). Out of 376 patients treated, 50.3% experienced no complications or hospital stays longer than necessary and had a complete response to the treatment one month later. The chances of a good outcome were lower for patients with more health issues, larger tumors, or multiple nodules, indicating that personalized assessments could help determine who benefits most from RFA. Who this helps: This research benefits patients with liver cancer and their doctors by guiding treatment decisions.

Plain English
This research paper looked at how sarcopenia, or muscle loss, affects people with chronic liver disease, particularly focusing on differences between men and women. The study found that sarcopenia is more common in men and noted that inconsistent criteria for diagnosing the condition make it hard to compare findings across different studies. Understanding how sex influences sarcopenia is important because it can help improve care and outcomes for patients. Who this helps: Patients with chronic liver disease and healthcare providers managing their treatment.

Plain English
This study looked at the effects of a special form of silybin, combined with vitamins D and E, on patients with advanced liver disease who had successfully cleared the hepatitis C virus (HCV). Researchers found that patients taking silybin had a greater improvement in liver stiffness compared to those who did not, with a reduction of 2.05 points after six months and 2.79 points after twelve months. This is significant because despite clearing the virus, many patients still face worsening liver disease, and silybin may help slow that progression. Who this helps: This helps patients with advanced liver disease who have cleared HCV.

Plain English
The study looked at the success of Italy’s mass vaccination campaign against hepatitis B, which started in 1991 for children and teenagers. It found that the number of new hepatitis B cases dropped significantly, from 5.0 cases per 100,000 people in 1990 to just 0.4 in 2019. Among vaccinated children (ages 0-14), there were no new cases reported, and the rate for young adults (ages 15-24) also fell dramatically by 99.4%. This progress shows that the vaccination effort is very effective and is helping to nearly eliminate the virus in Italy, making it a leader in controlling hepatitis B in Europe. Who this helps: Patients at risk of hepatitis B, especially children and young adults.

Plain English
This study looked at how patients with primary biliary cholangitis (PBC) in Italy view their illness and its impact on their lives. Researchers surveyed 210 patients and found that common symptoms included fatigue (50.4%), itching (45%), and abdominal discomfort (30.4%), with fatigue affecting daily life the most. Most patients (80%) were happy with their treatment, but 26% wanted better communication with their doctors, highlighting the need for improved patient-doctor interactions and quicker referrals to specialists. Who this helps: This helps patients with PBC and their healthcare providers.

Plain English
This study looked at how COVID-19 affects people who have received liver transplants (LT). Out of 30 LT patients infected with COVID-19, half showed symptoms, and 16.66% required hospitalization, similar to the general population. While LT patients had a higher rate of symptoms, the overall hospitalization and death rates were comparable to non-transplanted individuals, meaning transplant status did not increase the likelihood of severe outcomes. Who this helps: This information benefits liver transplant recipients and their healthcare providers.

Plain English
This research paper looks at autoimmune liver diseases (AILDs), which include conditions like autoimmune hepatitis and primary biliary cholangitis. The study highlights that these diseases often affect younger individuals and can lead to severe liver damage or the need for a liver transplant. It emphasizes the importance of examining how gender differences influence these diseases, as this knowledge could lead to better treatments. Who this helps: This helps patients with autoimmune liver diseases.

Plain English
This study looked at how the COVID-19 pandemic affected the care of patients with liver cancer, specifically hepatocellular carcinoma (HCC). Researchers found that routine monitoring of HCC patients dropped significantly due to pandemic-related restrictions, making it harder to provide timely treatment. Adapting care strategies allowed healthcare providers to focus on those at highest risk of worsening disease, ensuring better safety for patients during this crisis. Who this helps: This helps patients with hepatocellular carcinoma and their doctors.

Plain English
This study looked at how well liver transplant recipients respond to the COVID-19 vaccine compared to healthy individuals. It found that 75% of vaccinated liver transplant patients developed antibodies three months after receiving two doses of the vaccine, but their antibody levels were much lower (about 73.9 AU/mL) compared to healthy controls (around 261 AU/mL). The researchers also identified that older age, a shorter time since transplantation, and the use of certain immunosuppressant drugs made it more likely for these patients not to respond to the vaccine. Who this helps: This research helps liver transplant patients, their doctors, and healthcare providers.

Plain English
In this study, researchers looked at how well two noninvasive methods—transient elastography (TE) and the enhanced liver fibrosis (ELF) score—can measure liver damage in patients with chronic hepatitis C who were treated with antiviral drugs. Among 119 patients, 94.1% achieved a favorable treatment outcome, but 90% still had advanced liver fibrosis. The correlation between the two testing methods was low, but both showed improvement in liver health over time. Who this helps: This helps patients with hepatitis C and their doctors find safer ways to monitor liver health without needing invasive procedures.

Plain English
This study looked at patients with coeliac disease (CD) and how often they develop fatty liver disease after starting a gluten-free diet. Of 221 patients, 65 (29.4%) had fatty liver when they were first diagnosed with CD, and 46.6% developed it after two years. The study also found that those with a new diagnosis of metabolic-associated fatty liver disease (MAFLD) had more insulin resistance and higher liver damage scores compared to those with non-alcoholic fatty liver disease (NAFLD), highlighting the need for closer monitoring of these patients. Who this helps: Patients with coeliac disease and their healthcare providers.

Plain English
This study looked at how a mix of plant extracts, including berberine, tocotrienols, and coffee extracts, affects liver health and body weight in mice with fatty liver disease caused by a high-fat diet. Researchers found that mice given the plant extracts weighed less, had better insulin sensitivity, and lower cholesterol levels compared to those on a high-fat diet only. Specifically, the treated mice had a significant decrease in liver fat and improved liver enzyme levels, indicating better liver function. Who this helps: This research could benefit patients with non-alcoholic fatty liver disease and healthcare providers looking for new treatment options.

Plain English
This study looked at how liver function changes after treating hepatitis C (HCV) in patients with liver cirrhosis, comparing those with only HCV to those who also had HIV. Among 1,350 patients, 85% of those with both infections saw improvements in their liver function after treatment, compared to 64.6% of those with just HCV. However, some patients still experienced worsening liver conditions even after the virus was cleared, highlighting that eliminating HCV doesn't completely resolve liver issues for everyone. Who this helps: This research helps patients with liver cirrhosis, particularly those co-infected with HIV, as well as their doctors in managing their treatment and care.

Plain English
This study looked at how coffee affects certain RNA molecules in mice with non-alcoholic fatty liver disease (NAFLD). The researchers found that giving decaffeinated coffee to mice on a high-fat diet helped them gain less weight, prevented liver damage, and reduced high blood sugar and cholesterol levels. Specifically, coffee helped restore levels of protective RNA while lowering harmful RNA associated with liver fibrosis, showing that coffee can play a role in protecting the liver. Who this helps: Patients with non-alcoholic fatty liver disease.

Plain English
This study looked at liver function tests in pregnant women and found that abnormal results occur in 3-5% of pregnancies. These abnormalities can be caused by different factors, including specific liver diseases related to pregnancy, such as cholestasis and HELLP syndrome, which can lead to serious health issues for both the mother and the baby if not treated quickly. Understanding how to properly assess and manage these liver issues is crucial for ensuring the health and safety of pregnant women and their children. Who this helps: This helps pregnant women and their healthcare providers.

Plain English
Researchers at a hospital in Italy studied how telemedicine helped patients with chronic liver disease during the COVID-19 lockdown. From March 9 to May 3, 2020, nearly 400 virtual visits were conducted, and among about 1,700 patients, none contracted COVID-19 or needed treatment changes. This shows that telemedicine allowed patients to receive necessary medical care safely during the pandemic. Who this helps: This benefits patients with chronic liver disease who need regular medical support.

Plain English
This study looked at how a combination of silybin, vitamin D, and vitamin E affects patients with nonalcoholic fatty liver disease (NAFLD). After six months, 60 treated patients showed significant improvement in their health markers compared to the 30 patients who did not receive treatment, and those with metabolic syndrome showed even better results. This is important because it highlights a potential effective treatment for a common liver disease that many people in the Western world face. Who this helps: This helps patients suffering from nonalcoholic fatty liver disease, especially those with metabolic syndrome.

Plain English
In this study, researchers looked at how a mix of plant extracts affects patients with non-alcoholic fatty liver disease (NAFLD), which is linked to insulin resistance and diabetes. They found that after six months, patients taking the plant extracts had significantly lower blood sugar and insulin levels, improved insulin sensitivity, and less fat in the liver compared to those who received a placebo. Specifically, glucose levels dropped by less than 0.001, insulin levels decreased by less than 0.01, and the overall liver fat measurement improved significantly. Who this helps: This helps patients with NAFLD improve their liver health and manage their blood sugar levels.

Plain English
This study compared two treatments for large liver tumors: laser ablation (LA) and transarterial chemoembolization (TACE). It found that LA is much more effective, with 63.4% of patients having a complete response compared to only 19.5% for TACE. Moreover, after three years, 55.4% of patients treated with LA were alive, compared to 48.8% for those treated with TACE, and LA resulted in a significantly lower recurrence rate of 19.5% compared to TACE's 75%. Who this helps: This helps patients with large hepatocellular carcinoma seeking better treatment options.

Plain English
This study looked at the effects of new antiviral treatments on the risk of liver cancer (hepatocellular carcinoma or HCC) in people with chronic hepatitis C. Although the treatment helped over 95% of patients get rid of the virus, the actual rates of new cancer cases were found to range from 0% to 7.4%, and rates of cancer returning varied from 0% to 54.4%. The findings are complicated because different studies used different methods and had varying quality, but overall, there is no clear evidence that these new treatments increase the risk of liver cancer. Who this helps: This research benefits patients with hepatitis C and their doctors by providing clarity on cancer risks associated with new antiviral treatments.

Plain English
This study looked at the rates of Hepatitis C virus (HCV) infection in Naples, Italy, focusing on a diverse adult population. Out of 1,315 participants, 3% tested positive for HCV, with the highest rates found in people aged 60 and older, particularly those from lower-income areas. Understanding these trends is crucial for targeting treatment and prevention efforts, especially for older adults who may be unaware of their infection. Who this helps: Patients, especially older adults and those from lower socioeconomic backgrounds.

Plain English
This study looked at how certain viral infections (HBV and HCV) reactivate in patients with lymphoma who are treated with chemotherapy, especially those receiving a drug called rituximab. Out of 322 patients, 47 had hidden HBV, and 2 of the 7 treated with rituximab experienced reactivation, with one not using virus-preventing medication. No reactivation was found in the 8 patients with HCV positivity. Understanding these risks is vital because it shows that not all lymphoma treatments have the same effect on viral infections, which can help doctors better protect patients during cancer treatment. Who this helps: This helps patients with lymphoma and their doctors.

Plain English
This study looked at the rates of Hepatitis B (HBV) infection in the metropolitan area of Naples, Italy, to see how effective the universal vaccination campaign has been after 24 years. Among 900 adults surveyed, only 1.7% tested positive for the virus, showing that the vaccination is working well, especially since no vaccinated individuals had the infection. However, older adults and those from lower socioeconomic backgrounds were more likely to show signs of past infection, highlighting ongoing risk factors. Who this helps: This research benefits patients at risk for Hepatitis B, healthcare providers, and public health officials.

Plain English
This study looked at how chronic liver disease (CLD) affects bone health, highlighting that patients with CLD are at a higher risk of developing osteoporosis, which can lead to fractures and negatively impact their quality of life and survival rates. The authors reviewed recent research and found that osteoporosis is common in various types of liver disease, emphasizing the need for better management to reduce this risk and improve patients' lives. Overall, as treatments for liver disease improve, it's essential to also focus on preventing bone-related complications. Who this helps: This helps patients with chronic liver disease and their healthcare providers.